Ziconotide products: information for supporting intrathecal risk assessment

John Minshull, Deputy Director, London Medicines Information Service, Specialist Pharmacy ServicePublished

Ziconotide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration

Licensed for intrathecal use

Products licensed for intrathecal use are the first line option and should be used wherever suitable.

Intrapharm (Prialt®)

Strength

100mcg/ml in 1mL vial
100mcg/ml in 5mL vial

No information available

Products with very little or no information are rarely used for intrathecal administration.

There are currently no known additional ziconotide products.

All our intrathecal product resources

Understand what to consider when giving medicines via the intrathecal route and use our material to help inform your risk assessment

Learn more about us or ask for help

Ziconotide products vary in their licensed status and other characteristics which affects their suitability for intrathecal administration
If you're a healthcare professional who needs further advice, get in touch with us. We answer questions about Medicines Optimisation issues, including those about the COVID-19 vaccination programme. Help us to help you: tell us where on our site you were.